Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic h
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
01:33pm, Tuesday, 12'th May 2026
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that mod
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
04:01pm, Monday, 11'th May 2026
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that mod
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
09:36am, Wednesday, 22'nd Apr 2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breache
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
07:00am, Tuesday, 07'th Apr 2026
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and oth
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independen
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
09:00pm, Tuesday, 10'th Mar 2026
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:01pm, Tuesday, 10'th Mar 2026
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules th
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
07:00am, Thursday, 05'th Mar 2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and o
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of “Moderate Buy” from Analysts
02:08am, Friday, 13'th Feb 2026
Shares of Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, Marketbe
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year
01:26pm, Monday, 02'nd Feb 2026
Skye Bioscience, Inc. (NASDAQ: SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab.
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
07:00am, Monday, 02'nd Feb 2026
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nim
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
07:00am, Thursday, 29'th Jan 2026
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and othe
Skye Bioscience to Present Poster at Keystone Obesity Conference
07:00am, Wednesday, 21'st Jan 2026
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and othe
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
11:19am, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breach
